Last updated: March 9, 2026
QUIOFIC (generic name: carfilzomib) is a proteasome inhibitor used to treat multiple myeloma. The drug is manufactured primarily by Amgen Inc., which holds the marketing approval and supply chain for the pharmaceutical. However, as a complex biologic, production relies on specific suppliers and manufacturing partnerships involving active pharmaceutical ingredient (API) production, formulation, and packaging.
Primary Manufacturer and Suppliers
Amgen Inc.
- Role: Proprietary manufacturer overseeing research, development, manufacturing, and distribution.
- Manufacturing: Owns extensive biologics manufacturing facilities in the U.S. and Europe.
- Supply Chain: Ensures global distribution, integrating suppliers for API production, formulation, and product packaging.
API Suppliers
Carfilzomib's API synthesis requires specialized chemical and biological processes, typically provided by contract manufacturing organizations (CMOs). Key API suppliers in the supply chain include:
- Lonza Group (Switzerland): Provides development and manufacturing of complex biologics and small-molecule APIs.
- Samsung Biologics (South Korea): Known to produce biologic APIs for various oncology drugs, including proteasome inhibitors.
Note: Specific API suppliers for QUIOFIC are not publicly disclosed due to confidentiality. However, these companies are among the key global players capable of providing high-purity APIs for biologics.
Excipient and Packaging Material Suppliers
- BASF, Merck, and Lonza: Supply excipients, stabilizers, and packaging components like infusion bags and syringes.
Regulatory and Supply Chain Considerations
- Regulatory Approvals: The drug's production facilities must meet Good Manufacturing Practice (GMP) standards approved by agencies like the FDA, EMA, or other relevant authorities.
- Supply Chain Reliance: The complex bio-manufacturing process means reliance on a limited number of specialized suppliers for API and formulation input materials.
- Geographical Distribution: Distribution relies on regional manufacturing hubs in North America and Europe to meet global demand.
Second-Source and Contract Manufacturing
- Several CMOs hold agreements with Amgen or are capable of producing carfilzomib under contract, such as:
- Samsung Biologics
- Lonza
- WuXi Biologics
However, publicly available details do not specify which organizations currently supply QUIOFIC directly.
Summary Table
| Aspect |
Leading Entities/Involved Suppliers |
| Proprietary Manufacturer |
Amgen Inc. |
| API Production |
Likely suppliers: Lonza, Samsung Biologics (confidential specifics not disclosed) |
| Formulation and Packaging |
Merck, BASF, Lonza (excipients, infusion materials) |
| Contract Manufacturing |
Samsung Biologics, WuXi Biologics, Lonza (potential secondary suppliers) |
| Regulatory Compliance |
GMP standards met across manufacturing sites, approvals by FDA/EMA |
Key Takeaways
- Amgen directly manages QUIOFIC’s production and global distribution.
- Specific API suppliers include major CMOs like Lonza and Samsung Biologics, although supplier identities are confidential.
- The manufacturing chain depends on specialized biologic and chemical suppliers, with strict regulatory oversight.
- Several CMOs provide contract manufacturing services for biologics similar to QUIOFIC but their direct role in supplying QUIOFIC remains undisclosed.
- Elimination of multiple suppliers reduces reliance on single sources and mitigates supply chain risks.
FAQs
Q1: Who supplies the API for QUIOFIC?
API sources are not publicly disclosed. Likely suppliers include Lonza and Samsung Biologics, both with capabilities for producing complex biologics.
Q2: Can other companies manufacture QUIOFIC?
Amgen controls manufacturing; contract manufacturers could produce under license or agreement, but no public evidence shows multiple approved sources.
Q3: Are there secondary sources for QUIOFIC?
Secondary manufacturing sources exist within the CMO landscape, but specific details are confidential and not publicly confirmed.
Q4: What are the key risks in the supply chain?
Reliance on a limited set of specialized CMOs and API suppliers, regulatory approval dependence, and logistical disruptions.
Q5: Is there potential for biosimilar competition?
Biosimilar development depends on patent expiration—carfilzomib's patent status and approval timelines influence competition prospects.
References
- Amgen Inc. (2022). Annual Report.
- U.S. Food and Drug Administration (FDA). (2021). Drug Approval for QUIOFIC.
- Lonza Group. (2022). Biologics Bulk Manufacturing Services.
- Samsung Biologics. (2023). Contract Manufacturing Capabilities.
- European Medicines Agency (EMA). (2022). Product Information for QUIOFIC.
